Abstract: The present disclosure relates to oral pharmaceutical formulations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R, A and n are as described herein. The present disclosure also relates to processes for their preparation and their use in treating disorders such as cardiovascular and metabolic disorders, including diabetes.
| # | Name | Date |
|---|---|---|
| 1 | 202617025997-TRANSLATION OF PRIORITY DOCUMENTS ETC. [05-03-2026(online)].pdf | 2026-03-05 |
| 2 | 202617025997-STATEMENT OF UNDERTAKING (FORM 3) [05-03-2026(online)].pdf | 2026-03-05 |
| 3 | 202617025997-PRIORITY DOCUMENTS [05-03-2026(online)].pdf | 2026-03-05 |
| 4 | 202617025997-FORM 18 [05-03-2026(online)].pdf | 2026-03-05 |
| 5 | 202617025997-FORM 1 [05-03-2026(online)].pdf | 2026-03-05 |
| 6 | 202617025997-DECLARATION OF INVENTORSHIP (FORM 5) [05-03-2026(online)].pdf | 2026-03-05 |
| 7 | 202617025997-COMPLETE SPECIFICATION [05-03-2026(online)].pdf | 2026-03-05 |
| 8 | 202617025997-Proof of Right [07-04-2026(online)].pdf | 2026-04-07 |
| 9 | 202617025997-FORM-26 [07-04-2026(online)].pdf | 2026-04-07 |
| 10 | 202617025997-WIPO_PCT_DOC.pdf | 2026-04-08 |
| 11 | 202617025997-Proof of Right [09-04-2026(online)].pdf | 2026-04-09 |
| 12 | 202617025997-FORM-26 [09-04-2026(online)].pdf | 2026-04-09 |
| 13 | 202617025997-PATENT_APPLICATION_PUBLICATION.pdf | 2026-05-02 |